Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press134410.17650/1726-9784-2022-21-3-10-22REVIEWSОБЗОРЫ ЛИТЕРАТУРЫCurrent approaches to assessing the biological activity of immunocytokines in vitroАктуальные подходы к оценке биологической активности иммуноцитокинов в условиях in vitrohttps://orcid.org/0000-0003-0130-2628KonoplinaK. M.КоноплинаК. М.
Russian Federation

Ksenia Mikhailovna Konoplina

24 Kashirskoe Shosse, Moscow 115522

Ксения Михайловна Коноплина 

115522 Москва, Каширское шоссе, 24

konoplinakm@gmail.comhttps://orcid.org/0000-0002-4660-8519KosobokovaE. N.КособоковаЕ. Н.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-8462-2178KosorukovV. S.КосоруковВ. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России3110202221310223010202230102022https://bioterapevt.abvpress.ru/jour/article/view/1344

The use of cytokines as anticancer drugs is limited due to their toxicity. It is possible to reduce toxicity and to increase the therapeutic index by using cytokines in the form of conjugates with antibodies – immunocytokines. The results of preclinical studies have shown increased efficacy and reduced toxicity of various immunocytokines compared to the original, unconjugated cytokines. The potential of immunocytokines as anticancer agents is currently being studied in clinical trials. The therapeutic efficacy of immunocytokines depends on their physicochemical parameters, which determine the in vivo biodistribution, and biological activity as a result of the mechanisms of the antibody action and cytokine sites incorporated in the design. There is a need for methods that allow to assess the biological activity of both individual sites and the entire immunocytokine molecule when characterizing immunocytokines at an early stage of research.This review considers the existing approaches for assessing the biological activity of immunocytokines in vitro in the course of preclinical studies, such as monolayer cultures, reporter cell lines, co-cultures, three-dimensional (3D) tumor models. Monolayer cultures are sufficient to confirm the mechanism of action of separate sites of immunocytokines used in the design, and the “gold standard” test systems for determining the specific biological activity of the cytokine and the effector functions of the antibody site remain in demand. Commercial reporter cell lines remain an alternative option for assessing the biological activity of cytokine and antibody sites at the level of activation of signaling pathways. Co-cultures of tumor and effector cells make it possible to evaluate the cytotoxic and immunomodulatory effects of antibody and cytokine sites without using 3D cultivation methods. The use of 3D tumor models makes it possible to replace several tests for the biological activity of separate sites of immunocytokines conducted on monolayer cultures and co-cultures with one comprehensive study, however, such models require significant time and material costs.

В настоящем обзоре рассматриваются существующие подходы к оценке биологической активности иммуноцитокинов in vitro в ходе доклинических исследований: с использованием монослойных клеточных культур, репортерных клеточных систем, совместных культур, трехмерных (3D) моделей опухолей. Монослойных культур достаточно для подтверждения используемого в дизайне иммуноцитокина механизма действия его отдельных участков, и  тест-системы «золотого стандарта» для определения специфической биологической активности цитокина и эффекторных функций антительного участка остаются востребованными. Коммерческие репортерные клеточные системы являются альтернативным вариантом оценки биологической активности цитокинового и антительного участков на уровне активации сигнальных путей. Совместные культуры опухолевых и эффекторных клеток позволяют оценить цитотоксический и иммуномодулирующий эффекты антительного и цитокинового участков без использования методов 3D-культивирования. Использование 3D-моделей опухолей позволяет заменить несколько тестов на биологическую активность отдельных участков иммуноцитокина, проводимых на монокультурах и совместных культурах, на одно комплексное исследование, однако такие модели требуют значительных временных и материальных затрат.

immunocytokinebiological activitymechanism of actionиммуноцитокинбиологическая активностьмеханизм действияThis work was supported by the Ministry of Science and Higher Education of the Russian Federation, agreement № 075-15-2021-1060.Работа выполнена при поддержке Министерства науки и высшего образования Российской Федерации, соглашение № 075-15-2021-1060.Berraondo P., Sanmamed M.F., Ochoa M.C. et al. Cytokines in clinical cancer immunotherapy. Br J Cancer 2019;120(1):6–15. DOI: 10.1038/s41416-018-0328-yConlon K.C., Miljkovic M.D., Waldmann T.A. Cytokines in the treatment of cancer. J Interferon Cytokine Res 2019;39(1):6–21. DOI: 10.1089/jir.2018.0019Hutmacher C., Neri D. Antibody-cytokine fusion proteins: biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev 2019;141:67–91. DOI: 10.1016/j.addr.2018.09.002Collins S., Joshi A., Shen L. et al. 357 TAK-573, an anti-CD38-attenuated interferon alpha (IFNα) fusion protein (AttenukineTM), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma. J Immunother Cancer 2020;8:Suppl 3. DOI: 10.1136/jitc-2020-SITC2020.0357Runbeck E., Crescioli S., Karagiannis S.N., Papa S. Utilizing immunocytokines for cancer therapy. Antibodies (Basel) 2021;10(1):10. DOI: 10.3390/antib10010010Kaufman H.L., Mehnert J.M., Cuillerot J.-M. et al. Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: assessment of safety, clinical, and biologic activity in a phase 2a study. J Clin Oncol 2014;32(15 suppl):TPS9107. DOI: 10.1200/jco.2014.32.15_suppl.tps9107Overgaard N.H., Fan T.M., Schachtschneider K.M. et al. Of mice, dogs, pigs, and men: choosing the appropriate model for immuno-oncology research. ILAR J 2018;59(3):247–62. DOI: 10.1093/ilar/ily014Neri D. Antibody-cytokine fusions: versatile products for the modulation of anticancer immunity. Cancer Immunol Res 2019:7(3):348–54. DOI: 10.1158/2326-6066.CIR-18-0622Young P.A., Morrison S.L., Timmerman J.M. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol 2014;41(5):623–36. DOI: 10.1053/j.seminoncol.2014.08.002Gillies S.D., Lan Y., Lo K.M. et al. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res 1999;59(9):2159–66.Wahab S., Hussain A. Cytokines as targets for immunomodulation. Int J Pharm Pharm Sci 2013;5:60–4.Zou G.M., Tam Y.K. Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw 2002;13(2):186–99.Gillies S.D., Lan Y., Hettmann T. et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011;17(11):3673–85. DOI: 10.1158/1078-0432.CCR-10-2921Pogue S.L., Taura T., Bi M. et al. Targeting attenuated interferon-α to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity. PLoS ONE 2016;11(9):e0162472. DOI: 10.1371/journal.pone.0162472Klein C., Waldhauer I., Nicolini V.G. et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 2017;6(3):e1277306 DOI: 10.1080/2162402x.2016.1277306Klein C., Inja W., Nicolini V. et al. Abstract PR8: Novel tumortargeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer. Cancer Res 2013;73:PR8.Hemmerle T., Neri D. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo. Cancer Immunol Res 2014;2(6):559–67. DOI: 10.1158/2326-6066.cir-13-0182Kaspar M., Trachsel E., Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007;67(10):4940–8. DOI: 10.1158/0008-5472.CAN-07-0283Tzeng A., Kwan B.H., Opel C.F. et al. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A 2015;112(11):3320–5. DOI: 10.1073/pnas.1416159112Gillies S.D. A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity. Protein Eng Des Sel 2013;26(10):561–9. DOI: 10.1093/protein/gzt045Mock J., Stringhini M., Villa A. et al. An engineered 4-1BBL fusion protein with “activity on demand”. Proc Natl Acad Sci U S A 2020;117(50):31780–8. DOI: 10.1073/pnas.2013615117Venetz D., Koovely D., Weder B., Neri D. Targeted reconstitution of cytokine activity upon antigen binding using split cytokine antibody fusion proteins. J Biol Chem 2016;291(35):18139–47. DOI: 10.1074/jbc.M116.737734Kosobokova E.N., Sheshukova E.V., Pinyugina M.V. et al. Development of technology for producing of fusion protein based on humanized monoclonal antibody to tumor HER2 antigen and recombinant human interferon-α-2b in Nicotiana benthamiana. Biotekhnologiya = Biotechnology 2019;35(2):49–57. (In Russ.). DOI: 10.21519/0234-2758-2019-35-2-49-57Кособокова Е.Н., Шешукова Е.В., Пинюгина М.В. и др. Разработка технологии получения слитного белка на основе моноклонального гуманизированного антитела против опухолевого антигена HER2 и интерферона-α-2b человека из Nicotiana benthamiana. Биотехнология 2019;35(2):49–57. DOI: 10.21519/0234-2758-2019-35-2-49-57Mire-Sluis A.R., Page L., Thorpe R. Quantitative cell line based bioassays for human cytokines. J Immunol Methods 1995;187(2):191–9. DOI: 10.1016/0022-1759(95)00220-1Dakhel S., Lizak C., Matasci M. et al. An attenuated targetedTNF localizes to tumors in vivo and regains activity at the site of disease. Int J Mol Sci 2021;22(18):10020. DOI: 10.3390/ijms221810020Jiang X.R., Song A., Bergelson S. et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011;10(2):101–10. DOI: 10.1038/nrd3365Fenerty K.E., Padget M., Wolfson B. et al. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. J Immunother Cancer 2018;6(1): 133. DOI: 10.1186/s40425-018-0445-4Xi B., Ye P.F., Golubovskaya V., Abassi Y. In vitro functional assay using real-time cell analysis for assessing cancer immunotherapeutic agents. In: Immuno-oncology. Cellular and translational approaches. Ed. by S.L. Tan. Humana, N.Y., 2020. P. 35–50. DOI: 10.1007/978-1-0716-0171-6_3Li Z., Zhu Y., Li C. et al. Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer. Oncoimmunology 2017;6(3):e1290038. DOI: 10.1080/2162402X.2017.1290038Wang L., Yu C., Wang J. Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. Biotechnol Adv 2020;39:107466. DOI: 10.1016/j.biotechadv.2019.107466Liu J., Liu R., Gray P. et al. Development of a luciferase reporter Jurkat cell line under the control of endogenous interleukin-2 promoter. J Immunol Methods 2017;451:48–53. DOI: 10.1016/j.jim.2017.08.006Mock J., Pellegrino C., Neri D. A universal reporter cell line for bioactivity evaluation of engineered cytokine products. Sci Rep 2020;10(1):3234. DOI: 10.1038/s41598-020-60182-4Brancato V., Oliveira J.M., Correlo V.M. et al. Could 3D models of cancer enhance drug screening? Biomaterials 2020;232:119744. DOI: 10.1016/j.biomaterials.2019.119744Bregenzer M.E., Horst E.N., Mehta P. et al. Integrated cancer tissue engineering models for precision medicine. PLoS ONE 2019;14(5):e0216564. DOI: 10.1371/journal.pone.0216564Dhiman N., Kingshott P., Sumer H. et al. On-chip anticancer drug screening – recent progress in microfluidic platforms to address challenges in chemotherapy. Biosens Bioelectron 2019;137:236–54. DOI: 10.1016/j.bios.2019.02.070Herter S., Morra L., Schlenker R. et al. A novel threedimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. Cancer Immunol Immunother 2017;66(1):129–40. DOI: 10.1007/s00262-016-1927-1Soerensen M.M., Ros W., Rodriguez-Ruiz M.E. et al. Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP). J Clin Oncol 2018;36(15 suppl):e15155. DOI: 10.1200/JCO.2018.36.15_suppl.e15155Ayuso J.M., Truttschel R., Gong M.M. et al. Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology 2019;8(3):1553477. DOI: 10.1080/2162402X.2018.1553477Gladkov O., Biakhov M., Ramlau R. et al. Phase II trial of huKSIL2 with cyclophosphamide (CTX) in patients with extensive disease small-cell lung cancer (ED-SCLC). J Clin Oncol 2012;30(15 Suppl):7090. DOI: 10.1200/jco.2012.30.15_suppl.7090Jaekel A., Kehler P., Lischke T. et al. Preclinical characterization of GT-00A x IL15: a novel IL-15-based immunocytokine with unique tumor targeting properties. J Immunother Cancer 2021;9(Suppl 2):A741. DOI: 10.1136/jitc-2021-SITC2021.712